TEVA-CLONIDINE TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

CLONIDINE HYDROCHLORIDE

제공처:

TEVA CANADA LIMITED

ATC 코드:

C02AC01

INN (국제 이름):

CLONIDINE

복용량:

0.2MG

약제 형태:

TABLET

구성:

CLONIDINE HYDROCHLORIDE 0.2MG

관리 경로:

ORAL

패키지 단위:

100/500

처방전 유형:

Prescription

치료 영역:

CENTRAL ALPHA-AGONISTS

제품 요약:

Active ingredient group (AIG) number: 0108891002; AHFS:

승인 상태:

APPROVED

승인 날짜:

2013-12-13

제품 특성 요약

1
PRODUCT MONOGRAPH
PR
TEVA-CLONIDINE
(Clonidine Hydrochloride)
0.1 mg and 0.2 mg Tablets
USP
Antihypertensive
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Submission Control No: 171843
Date of Revision:
April 25, 2014
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY
PRODUCT
INFORMATION
................................................................................
3
INDICATIONS
AND
CLINICAL
USE
......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
3
WARNINGS
AND
PRECAUTIONS
.........................................................................................
4
ADVERSE
REACTIONS
...........................................................................................................
7
DRUG
INTERACTIONS
............................................................................................................
9
DOSAGE
AND
ADMINISTRATION
......................................................................................
11
OVERDOSAGE
........................................................................................................................
12
ACTION
AND
CLINICAL
PHARMACOLOGY
....................................................................
13
STORAGE
AND
STABILITY
.................................................................................................
14
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ..................................................... 14
PART II: SCIENTIFIC INFORMATION
...............................................................................
16
PHARMACEUTICAL
INFORMATION
.................................................................................
16
DETAILED
PHARMACOLOGY
............................................................................................
17
TOXICOLOGY
...........................